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Nanocomposition comprised of interleukin-2 in suboptimal noneﬀective concentration and β-cyclodextrin was studied in vitro.
This preparation as well as interleukin-2 in optimal concentration was shown to increase natural killer activity to K-562 cells
and cytotoxicity of activated peripheral blood mononuclear cells (PBMCs) against PC-3 and DU 145 cells. At the same time
β-cyclodextrin or interleukin-2 in equimolar concentrations did not inﬂuence the spontaneous killer activity of PBMC. This
combination of cyclodextrin + interleukin-2 led to the decrease of interleukin-2 eﬀective concentration by an order. This phe-
nomenon could be explained by cyclodextrins ability to promote the formation of nanoparticles with drugs, which results
in enhancing their water solubility and bioavailability. Besides, interleukine-2/β-cyclodextrin nanocomposition as opposed to
interleukin-2 alone led to increasing the number of not only lymphocytes, but also macrophages contained in activated PBMC
population. Application of low concentration of interleukin-2 allowing for good clinical eﬃciency may signiﬁcantly mitigate the
side eﬀects of the drug and enable to develop adoption of immunotherapy for patients with androgen-resistant prostate cancer.
1.Introduction
Prostate cancer is one of the most leading causes of death
in men. In 2008 in the USA 286660 new deaths for prostate
cancerwereregistered[1].Prostatecanceraccountsforabout
12% of male deaths of cancer in the UK [2] and 10% in the
USA[1]andisthesecondmostleadingcauseofcancerdeath
in men, after lung cancer. The majority of prostate cancer
deaths (93%) occur in men aged 65 and over. In elder men
aged 85 and over, prostate cancer overtakes lung cancer to
become the most common cause of cancer deaths [3]. Two-
stage development is characteristic for such kind of tumor,
an androgen-dependent stage, when antiandrogen therapy is
still eﬀective, and androgen-resistant stage, when antiandro-
gen therapy does not work. The period of positive response
towards antiandrogen therapy is limited and as a result most
of the tumors enter the androgen-therapy-resistant stage.
This signiﬁcantly restricts therapeutic inventory and thus
results in disappointing prognosis for patients.
Until recent times hormone-resistant prostate cancer has
been considered incurable, and main therapeutic eﬀorts
have been applied towards life quality improvement for
the patients aﬀected by painful bone metastases. Therefore,
over recent years prostate cancer biotherapy methods have
been developed. Clinical trials with immune active agents
reported in the last years have demonstrated eﬃcacy in the
treatment of prostate cancer. These agents include immune
modulators, antibody targeting prostate-speciﬁc membrane
antigen, and vaccines such as those targeting prostatic acid
phosphatase, prostate-speciﬁc antigen, and cellular vaccines
expressing granulocyte-macrophage colony stimulating fac-
tor [4–6]. Results from several recent clinical trials have2 ISRN Oncology
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Figure 1: NK activity of IL-250/CD cells versus control ML, LAK,
CD cells, and IL-250 cells (IL-2 cells (50U/mL)), ∗P<0.05.
Figure 2: Microphoto of LAK after 18h coincubation with K-562
(×100). MTT added.
suggested that immune-based therapies have clinical beneﬁt
in patients with prostate cancer with potentially less toxicity
than traditional treatments [7–9].
Immunotherapy mediated by cytotoxic lymphocytes and
lymphokine-activated lymphocytes (LAKs) was shown to be
powerful in the destruction of drug-resistant tumor cells.
Usually LAK generation requires recombinant interleukin-2
(IL-2).Theselymphocyteskilltargetcellsbytwomainmech-
anisms, namely the perforin pathway and the Fas-ligand
(Fas-L) pathway. The androgen-independent prostate cells
(AIPC) PC-3 and DU 145 express Fas on the cell surface
but they are resistant to killing by anti-Fas antibody. AIPC is
sensitive to killing by LAK, and the cell killing was primarily
mediated through the Ca(2+)-dependent perforin pathway
[10]. Since IL-2/LAK therapy has not proved to be clinically
eﬀective, improvement in eﬃciency and mitigation of sys-
temic side eﬀects are warranted. This improvement implies
the development and the introduction of mononuclear
leukocytes (MLs) activated by exogenous cytokines,o rn e w
methods of their cultivation. For this purpose liposomal and
pegylated drug forms of interleukin-2 have been synthesized
[11, 12].
Cyclodextrins, natural or synthetic polysaccharides,a s
nanocarriers for bioactive compounds oﬀer new opportu-
nities [13–15]. Thus, MLs of C3H/He mice activated by
mixture of IL-2 and β-cyclodextrin-benzaldehyde possessed
Figure 3: Microphoto of IL-250/CD cells after 18h coincubation
with K-562 (×100). MTT added.
Figure 4: Microphoto of IL-250 cells after 18h coincubation with
K-562 (×100). MTT added.
higher antitumor cytotoxic activity as compared to MLs acti-
vated only by IL-2 or β-cyclodextrin-benzaldehyde [16]. In
this paper the inﬂuence of nanocomposition based on IL-
2 in suboptimal concentration and β-cyclodextrin (β-CD)
on immunophenotype and cytotoxic activity of ML towards
p r o s t a t ec a n c e rc e l l so fD U1 4 5a n dP C - 3t y p e s ,a sw e l la s
towards NK-sensitive K-562 cell, was studied.
2.MaterialsandMethods
2.1. Preparation of IL-2/β-CD Nanocomposition. Equal vol-
umes of IL-2 solution “Proleukin” (Chiron, The nether-
Pands) at the concentration level of 1000IU in CM and β-
CD (Sigma, USA) at the concentration level of 2 × 10−4 M
in dimethylsulfoxide (DMSO) were mixed. The mixture
was incubated at 30◦C with the use of ST-3L shaker
(ELMI,Latvia)under800–1200rpmfor45–60min.Theﬁnal
concentrations of components in nanocomposition were
500IU/mL for IL-2, 1 × 10−4 Mf o rβ-CD, and 50% DMSO
in CM.
2.2. Cell Generation
2.2.1. ML Extraction. ML was extracted from heparin sta-
bilized periphery blood of healthy donor at ﬁcoll-urograﬁn
gradient 1.077g/cm3 (Sigma, USA) with the use of centrifu-
gation under 400g during 20–30 minutes. Lymphoid cellsISRN Oncology 3
Figure 5: Microphoto of control ML after 18h. coincubation with
K-562 (×100). MTT added.
Figure 6: Microfoto of control ML after 18h. coincubation with
K-562 (×100). MTT added.
forming interphase ring were collected and washed out
three times with RPMI-1640 medium (Sigma, USA). Cells
were concentrated by centrifugation, calculated with the
help of 5% trypan blue solution (PanEco, Russia), and then
resuspended in complete medium (CM). CM is RPMI-1640
containing 10% of fetal bovine serum (HyClone Laborato-
ries, Logan, UK) inactivated at 56◦Cf o r3 0 m i n ,2 m ML -
glutamine, 100μg/mL of penicillin and 100ug/mL of strep-
tomycin sulfate (PanEco, Russia). The concentration of the
cells in suspension was equal to 5 × 105-6 × 105 cell/mL.
2.2.2. LAK (IL-2500 Cells) Generation. The suspension of ML
(5mL) was mixed with IL-2 solution at the concentration
level of 1000U in CM (5mL). The active concentration of
IL-2 in the solution was 500IU/mL. Cells were incubated in
plastic ﬂacks of 100mL volume in CO2 incubator for 48h at
37◦Ci n5 %C O 2 atmosphere.
2.2.3. IL-250 Cells Generation. The suspension of ML
(9.5mL) was mixed with IL-2 solution at the concentration
level of 1000IU in CM (0.5mL). The active concentration of
IL-2 in the solution was 50IU/mL. Cells were incubated in
plastic ﬂacks of 100mL volume in CO2 incubator for 48h at
37◦Ci n5 %C O 2 atmosphere.
2.2.4. IL-250/β-CD Cells Generation. The suspension of ML
(4.5mL) was mixed with IL-2/β-CD composition (0.5mL).
The active concentrations of components in the solution
were 50IU/mL for IL-2, 1 × 10−5 Mf o rβ-CD, and 5%
for DMSO. Cells were incubated in plastic ﬂacks of 100mL
volume (Costar, USA) in CO2-incubator (Guan, France) for
48h at 37◦Ci n5 %C O 2 atmosphere.
2.2.5. β-CD-Cells Generation. The suspension of ML
(4.5mL) was mixed with the solution of β-CD at the con-
centration level of 1 × 10−4 Mi nD M S O( 0 . 5m L ) .T h ea c t i v e
concentration of β-CD in the solution was 1 × 10−5 M.
Cells were incubated in plastic ﬂacks of 100mL volume in
CO2-incubator for 48h at 37◦Ci n5 %C O 2 atmosphere.
2.3. Antitumor Activity Assay. NK activity was determined
towards NK-sensitive human erythroleukemia cell line K-
562. Cytotoxic activity was estimated towards PC-3 and DU
145 AIPC cell lines. Tumor cells (1 × 104 in 1mLCM) were
incubated with IL-250/CD cells, LAK (IL-2500 cells), IL-250-
cells, β-CD cells and control ML at a ratio of 1:10 (K-
562) or 1:2 (PC-3 and DU 145) for 24h at 37◦Ci n5 %
CO2 atmosphere. MLs incubated with 5% DMSO were used
as a control. Cells were controlled and documented by
Axiovert (Zess, Germany). We added 20μLT h i a z o l y lB l u e
Tetrazolium Bromide (MTT) (Sigma, USA) 5g·L−1 to each
well of multiwell culture plate, incubated for 4 hours, then
added 150μL DMSO, mixed about 10min until the crystal
completely dissolved.
Index of cytotoxic activity (IC) was calculated from
optical density value measured by tray photometer (Mul-
tiscan MS, Finland) after addition of Thiazolyl Blue Tetra-
zolium Bromide (MTT) (Sigma, USA). IC, % = (1−
(OPCC+ML−OPML)/OPCC) × 100—OPCC+ML—optical den-
sity in the vessel containing cancer cells and ML, OPML—
optical density in the vessel containing ML only, OPCC —
optical density in the vessel containing cancer cells only.
2.4. Flow Cytometric Analysis. The cells were washed by PBS
and incubated with antihuman antibodies for 30min at 4◦C.
MLs were incubated with monoclonal antibodies speciﬁc for
human antigens CD. Antibodies used were anti-CD3, anti-
CD4, anti-CD16, anti-CD25, anti-CD56, anti-CD58, anti-
CD80,anti-CD11c,anti-CD83,andanti-HLA-DR(Beckman
Coulter, USA). Flow cytometric analysis was done using
a Coulter FC500 ﬂow cytometer (Coulter, USA).
2.5. Statistical Analysis. CellQuest and WinMDI.2.8. soft-
ware were used for statistical analysis of cell phenotype. All
statistical calculations were made using the software package
Statistica 6.0 using factor dispersion analysis (ANOVA/
MANOVA) and Mann-Whitney U test for group compar-
ison. In all cases, results were considered as statistically
signiﬁcant at P<0.05.
3. Results
3.1. NK Activity of Activated Cells. NK activity of IL-250/β-
CD cells, LAK, IL-250 cells, β-CD cells, and control ML4 ISRN Oncology
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Figure 7: Induction of new cell populations of activated peripheral blood mononuclear cells versus control (SSC-H:site scatter height,
FSC-H:forward scatter height). (a) control ML, (b) LAK, (c) IL-250 cells, (d) CD cells, and (e) IL-250/CD cells.ISRN Oncology 5
Table 1: Phenotype of IL-250/ C Dc e l l s ,C Dc e l l s ,I L - 2 50 cells, and LAK versus control ML.
Surface cell markers Control ML LAK IL-250 cells CD cells IL-250/CD ML
CD3/CD16 5.86 16.56∗ 11.82 6.55 22.3∗
CD16 5.22 6.22 10.56 5.21 8.3
CD4/CD25 13.05 21.76∗ 18.82 11.16 19.14∗
CD25 2.58 5.21 1.8 4.7 7.8∗
CD58 4.18 29.32∗ 17.56 30.64∗ 34.45∗
HLA-DR 3.26 3.98 1.68 5.71∗ 5.22∗
CD80 0.57 0.78 0.47 0.14 0.26
CD80/CD83 9.81 12.42 9.18 11.25 14∗
CD83 2.89 3 3 4.43 2.59
CD11c 8 9.91 8.53 14.11 13.44∗
CD56/CD16 7.82 9.1 5.1 0 12.3∗
∗Signiﬁcant date versus control ML (P<0.05).
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Figure8:Cytotoxicactivityofactivatedcellsascomparedtocontrol
ML towards AIPC prostate cancer cell lines PC-3 and DU 145,
∗P<0.05.
was detected at NK-sensitive cells line K-562. The cancer
cell/eﬀector cell ratio was 1:10. LAK generated with high
concentration of IL-2 activated lysis of 67 ± 10, 1% K-562
cells as compared to control ML (IC = 46 ± 7.8%). IL-250/β-
CD cells activated by nanocomposition containing subop-
timal concentration of IL-2 demonstrated higher cytotoxic
activity (86 ± 7.2%), as compared to LAK (Figure 1). ML
incubation with β-CD as well as with low concentration
of IL-2 did not lead to cell killer activity stimulation. As
microphoto showed the IL-250/β-CD cells population as well
as LAK contained a large number of lymphocyte clusters that
indicated the proliferation of these cells (Figures 2 and 3).
On the contrary IL-250 cells had not organized such clusters
(Figure 4). Unlike LAK and control ML (Figure 5) the IL-
250/β-CD composition results in the generation of a large
number of adherent dendrite-like cells. Obviously this eﬀect
is caused by the activity of β-CD, which alone initiates the
appearance of similar cells (Figure 6).
3.2. Flow Cytometry Analysis. The analysis revealed that
the IL-250/β-CD cells population as opposed to control
cells has two cell regions (Figures 7(a), 7(b), 7(c), 7(d),
and 7(e)). The second additional IL-250/β-CD cells region
is obviously represented by large macrophage cells. IL-250/β-
C Dc e l lc u l t u r ea so p p o s e dt oI L - 2 50 cell is represented by
adherent cells, which is not typical for LAK. In particular,
increasingtheexpressionofNKmarkers(CD16/CD56),NK-
Tc e l l sm a r k e r s( C D 3 / C D 1 6 ) ,a sw e l la sa d h e s i o nm o l e c u l e s
(CD58), and receptor cell towards IL-2 (CD25) was detected
(Table 1). However, as compared to LAK, the population
of IL-250/β-CD cells contained a large number of antigen-
presenting, mature CD11c+ dendritic cells, which express
HLA-DR and CD80/CD83 cell markers represented mainly
in region 2.
3.3. Cytotoxic Activity of Cells Tested towards AIPC Cell Lines.
According to data presented in Figure 8 spontaneous killer
a ct i vi tyo fc o n tr o lM Lw a se q u a lt o4 1± 5.2% and 44 ± 8.0%
for PC-3 and DU 145 cells, respectively. IL-250 cells and β-
CD cells had almost the same activity as control ML (there
was no proved distinction revealed). LAK possessed better
cytotoxic potential and on the average lysed 72 ± 5.1% and
86 ± 8.2% PC-3 and DU 145 cells, respectively. IL-250/β-CD
cells were slightly more active against PC-3 and DU 145 cells,
(82 ± 5.2% and 88 ± 10.2%, resp.), as compared to LAK, but
that diﬀerence was not proved statistically.
4. Discussion
At present a therapy of hormone-resistant prostate can-
cer possesses very limited resources. In addition, modern
methods of chemotherapy and X-ray therapy often result in
side eﬀects, including immunosuppression and thus impair
patient’s life quality. The undermining of immunological
and antitumor status as a result of the treating may lead
to the disease progression. Therefore, it seems to be of
current interest to develop new methods of biotherapy of
hormone-resistant prostate cancer. At present diﬀerent types
ofdendritic-cells-basedvaccine,areundergoingclinicaltrials
[17, 18]. IL-2/LAK-immunotherapy can be considered to be
one of the top priority issues. This is proved by experimental6 ISRN Oncology
investigations which reveled high sensitivity of human AIPC
cells to cytotoxic activity of LAK [3].
As mice experiments have previously shown, the com-
bination of IL-2 and β-cyclodextrin-benzoic acid enables to
improve the LAK killer activity towards sarcoma cells [9]. It
was proved that β-CD composition with suboptimal non-
eﬀective concentration of IL-2 improves NK-activity, tested
on K-562, as well as cytotoxicity of ML against PC-3 and
DU 145. In this case equimolar concentration of β-CD itself
did not produce any signiﬁcant eﬀect upon spontaneous
killer activity of ML. This phenomenon can be explained by
the well-known ability of β-CD to improve water solubility
and biological availability of drugs, including IL-2 [13, 15].
Besides, unlike IL-2 itself, IL-2/β-CD nanocomposition leads
to increase in the number of not only lymphocytes but also
of macrophages/dendritic cellsin ML population as well. It is
well-known that macrophages and especially dendritic cells
(DCs) secrete cytokines, particularly IL-12, thus improving
IL-2 eﬀect. It is worth mentioning that IL-250/β-CD cells
population contains mature CD80+/CD83+ dendritic cells,
which express molecules of antigen presentation HLA-DR.
This can also prove the ability of IL-2/β-CD nanocomposi-
tion to activate eﬀectors of natural and adaptive immunity.
The main disadvantage of the current adoptive immun-
otherapy methods is the limited target eﬀect produced upon
one of the mentioned immune system components. In par-
ticular,DCvaccinesactionisaimedtothecreationofspeciﬁc
immune response to the tumor antigen. However, as tumor
is heterogenic, a part of the cells population does not express
cancer-associated antigens and MHC molecules enabling so
the neoplastic cells to escape an immune response eﬀect. In
contrast, LAK cells lyse cancer cells by antigen and MHC-
independent way [19]. MHC expression on cancer cells
downregulates NK and LAK activity [20, 21].
Application of IL-250/β-CD nanocomposition was sug-
gested to eliminate the above-mentioned methods draw-
backs because it provides a unique origin for LAK and DC.
Usually immune clinical cancer treatment involves the use of
high cytokine dose, reaching in the case of IL-2 dose near or
superiorto18000000IU.Thisdosecreatesserioussideeﬀects
[22] .T h ed a t aw eh a v eo b t a i n e dp r o v e st h a tI L - 2 / β-CD
nanocomposition enables to decrease eﬃcient concentration
of IL-2 at least by one order of magnitude. Hence, creation of
nanocapsulesbasedonβ-CDandcytokinesmaysigniﬁcantly
improve adoptive immunotherapy for cancer patients. The
potential of β- C Di nd r u gd e l i v e r ya p p l i c a t i o n sr e m a i n s
partially unexploited [23]. We have proved tested nanocom-
position to be highly eﬃcient towards AIPC cells. Therefore
further detailed preclinical studies aimed at creating new
eﬀective drugs and methods of immunotherapy of patients
with hormone-resistant prostate cancer are worth being
carried out.
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